1. Home
  2. MRCY vs MNKD Comparison

MRCY vs MNKD Comparison

Compare MRCY & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRCY
  • MNKD
  • Stock Information
  • Founded
  • MRCY 1981
  • MNKD 1991
  • Country
  • MRCY United States
  • MNKD United States
  • Employees
  • MRCY N/A
  • MNKD N/A
  • Industry
  • MRCY
  • MNKD Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRCY
  • MNKD Health Care
  • Exchange
  • MRCY Nasdaq
  • MNKD Nasdaq
  • Market Cap
  • MRCY 2.2B
  • MNKD 1.8B
  • IPO Year
  • MRCY 1998
  • MNKD 2004
  • Fundamental
  • Price
  • MRCY $40.94
  • MNKD $6.85
  • Analyst Decision
  • MRCY Hold
  • MNKD Strong Buy
  • Analyst Count
  • MRCY 8
  • MNKD 5
  • Target Price
  • MRCY $35.50
  • MNKD $8.40
  • AVG Volume (30 Days)
  • MRCY 490.0K
  • MNKD 3.2M
  • Earning Date
  • MRCY 11-05-2024
  • MNKD 11-07-2024
  • Dividend Yield
  • MRCY N/A
  • MNKD N/A
  • EPS Growth
  • MRCY N/A
  • MNKD N/A
  • EPS
  • MRCY N/A
  • MNKD 0.08
  • Revenue
  • MRCY $858,715,000.00
  • MNKD $267,200,000.00
  • Revenue This Year
  • MRCY $3.71
  • MNKD $46.83
  • Revenue Next Year
  • MRCY $6.49
  • MNKD $14.40
  • P/E Ratio
  • MRCY N/A
  • MNKD $86.27
  • Revenue Growth
  • MRCY N/A
  • MNKD 51.35
  • 52 Week Low
  • MRCY $25.31
  • MNKD $3.17
  • 52 Week High
  • MRCY $44.63
  • MNKD $7.63
  • Technical
  • Relative Strength Index (RSI)
  • MRCY 60.64
  • MNKD 49.71
  • Support Level
  • MRCY $38.32
  • MNKD $6.74
  • Resistance Level
  • MRCY $44.63
  • MNKD $7.04
  • Average True Range (ATR)
  • MRCY 1.83
  • MNKD 0.32
  • MACD
  • MRCY -0.03
  • MNKD -0.06
  • Stochastic Oscillator
  • MRCY 68.38
  • MNKD 24.94

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: